Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 295

1.

Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.

Przysiecki C, Lucas B, Mitchell R, Carapau D, Wen Z, Xu H, Wang XM, Nahas D, Wu C, Hepler R, Ottinger E, Ter Meulen J, Kaslow D, Shiver J, Nardin E.

Front Cell Infect Microbiol. 2012 Nov 30;2:146. doi: 10.3389/fcimb.2012.00146. eCollection 2012.

2.

Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.

Powell TJ, Tang J, Derome ME, Mitchell RA, Jacobs A, Deng Y, Palath N, Cardenas E, Boyd JG, Nardin E.

Vaccine. 2013 Apr 8;31(15):1898-904. doi: 10.1016/j.vaccine.2013.02.027. Epub 2013 Feb 26.

3.

Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.

McCoy ME, Golden HE, Doll TA, Yang Y, Kaba SA, Zou X, Gerbasi VR, Burkhard P, Lanar DE.

Malar J. 2013 Apr 22;12:136. doi: 10.1186/1475-2875-12-136. Erratum in: Malar J. 2013;12:356. Zou, Xiaoyan [added]; Gerbasi, Vincent R [added].

4.
5.

Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin.

Carapau D, Mitchell R, Nacer A, Shaw A, Othoro C, Frevert U, Nardin E.

Infect Immun. 2013 Dec;81(12):4350-62. doi: 10.1128/IAI.00263-13. Epub 2013 Sep 16.

6.

Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint.

Porter MD, Nicki J, Pool CD, DeBot M, Illam RM, Brando C, Bozick B, De La Vega P, Angra D, Spaccapelo R, Crisanti A, Murphy JR, Bennett JW, Schwenk RJ, Ockenhouse CF, Dutta S.

Clin Vaccine Immunol. 2013 Jun;20(6):803-10. doi: 10.1128/CVI.00066-13. Epub 2013 Mar 27.

7.

Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.

Burns JM Jr, Miura K, Sullivan J, Long CA, Barnwell JW.

Malar J. 2016 Mar 15;15:159. doi: 10.1186/s12936-016-1226-5.

8.

Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.

Khan F, Porter M, Schwenk R, DeBot M, Saudan P, Dutta S.

PLoS One. 2015 Nov 16;10(11):e0142035. doi: 10.1371/journal.pone.0142035. eCollection 2015.

9.

Antigenicity and immunogenicity of a novel chimeric peptide antigen based on the P. vivax circumsporozoite protein.

Céspedes N, Arévalo-Herrera M, Felger I, Reed S, Kajava AV, Corradin G, Herrera S.

Vaccine. 2013 Oct 1;31(42):4923-30. doi: 10.1016/j.vaccine.2013.05.082. Epub 2013 Aug 15.

10.

Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.

Othoro C, Johnston D, Lee R, Soverow J, Bystryn JC, Nardin E.

Infect Immun. 2009 Feb;77(2):739-48. doi: 10.1128/IAI.00974-08. Epub 2008 Dec 1.

11.

Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).

Udhayakumar V, Saekhou A, Fang S, Jue D, Wohlhueter RM, Lal AA.

Vaccine. 1998 May-Jun;16(9-10):982-8.

PMID:
9682348
12.

A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge.

Calvo-Calle JM, Oliveira GA, Watta CO, Soverow J, Parra-Lopez C, Nardin EH.

Infect Immun. 2006 Dec;74(12):6929-39. Epub 2006 Oct 9.

13.

Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein.

Iyori M, Nakaya H, Inagaki K, Pichyangkul S, Yamamoto DS, Kawasaki M, Kwak K, Mizukoshi M, Goto Y, Matsuoka H, Matsumoto M, Yoshida S.

PLoS One. 2013 Aug 12;8(8):e70819. doi: 10.1371/journal.pone.0070819. eCollection 2013.

14.

An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses.

Parra-López CA, Bernal-Estévez D, Yin L, Vargas LE, Pulido-Calixto C, Salazar LM, Calvo-Calle JM, Stern LJ.

PLoS One. 2014 Jul 1;9(7):e100639. doi: 10.1371/journal.pone.0100639. eCollection 2014. Erratum in: PLoS One. 2014;9(11):e113028. Yin, Liusong [added].

16.

Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes.

Phares TW, May AD, Genito CJ, Hoyt NA, Khan FA, Porter MD, DeBot M, Waters NC, Saudan P, Dutta S.

Malar J. 2017 Mar 13;16(1):115. doi: 10.1186/s12936-017-1766-3.

17.

Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice.

Moreno CA, Rodriguez R, Oliveira GA, Ferreira V, Nussenzweig RS, Moya Castro ZR, Calvo-Calle JM, Nardin E.

Vaccine. 1999 Aug 20;18(1-2):89-99.

PMID:
10501239
18.

Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.

Patra KP, Li F, Carter D, Gregory JA, Baga S, Reed SG, Mayfield SP, Vinetz JM.

Infect Immun. 2015 May;83(5):1799-808. doi: 10.1128/IAI.02980-14. Epub 2015 Feb 17.

19.

IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.

Schwenk R, DeBot M, Porter M, Nikki J, Rein L, Spaccapelo R, Crisanti A, Wightman PD, Ockenhouse CF, Dutta S.

PLoS One. 2014 Oct 24;9(10):e111020. doi: 10.1371/journal.pone.0111020. eCollection 2014.

20.

Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.

Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM, Anderson CA, Soundarapandian V, Ahumada A, Keler T, Hoffman SL, Nussenzweig MC, Steinman RM, Seder RA.

Vaccine. 2010 Oct 21;28(45):7256-66. doi: 10.1016/j.vaccine.2010.08.098. Epub 2010 Sep 21.

Supplemental Content

Support Center